TG Therapeutics Jumps 6% on 82% Response Rate in Briumvi MG Trial
TGTX•TG Therapeutics said 82% of 11 myasthenia gravis patients treated with at-home subcutaneous Briumvi showed meaningful improvement by week 24 with a median benefit in 30 days. It has initiated a larger mid-stage trial to pursue MG approval and broaden Briumvi’s use beyond multiple sclerosis.
1. Early-Stage Trial Results
In the preliminary study, 11 patients with myasthenia gravis received subcutaneous Briumvi and 82% achieved clinically meaningful improvement in daily activities by week 24, with most reporting symptom relief in about 30 days.
2. Safety Profile Comparable to IV
The at-home injectable form demonstrated a safety profile consistent with the already-approved intravenous Briumvi, with similar types and rates of adverse events observed during the study period.
3. Mid-Stage Trial and Expansion Plans
Following these encouraging results, the company has launched a larger mid-stage trial designed to support regulatory approval for MG and aims to evaluate long-term efficacy and dosing convenience compared to clinic infusions.
4. Stock Market Reaction
Shares of TG Therapeutics climbed approximately 6% in response to the data release, reflecting heightened investor optimism about the potential expansion of Briumvi’s indications and future revenue streams.
